中度至重度-话题@MedSci

#中度至重度#

52篇内容 | 825人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1796946, encodeId=319d1e9694633, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=JAMA Dermatol：特定配方的维A酸前体可有效治疗中度至重度面部光损伤, objectType=article, longId=736659, objectId=3b84e36659ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b84e36659ab, replyNumber=0, likeNumber=57, createdTime=2023-01-30, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b84e36659ab, moduleTitle=JAMA Dermatol：特定配方的维A酸前体可有效治疗中度至重度面部光损伤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b84e36659ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796945, encodeId=27071e969457e, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=J Am Acad Dermatol：阿布昔替尼可有效治疗中度至重度特应性皮炎，无论之前患者对度匹鲁单抗的反应如何, objectType=article, longId=733964, objectId=3601e3396485, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3601e3396485, replyNumber=0, likeNumber=40, createdTime=2023-07-06, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3601e3396485, moduleTitle=J Am Acad Dermatol：阿布昔替尼可有效治疗中度至重度特应性皮炎，无论之前患者对度匹鲁单抗的反应如何, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3601e3396485)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796941, encodeId=58b31e9694141, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=Allergy：中度至重度过敏成人中，草树过敏免疫疗法与安慰剂RQLQ评分的最小重要差异, objectType=article, longId=294489, objectId=d00b294489d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d00b294489d3, replyNumber=0, likeNumber=48, createdTime=2022-10-12, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d00b294489d3, moduleTitle=Allergy：中度至重度过敏成人中，草树过敏免疫疗法与安慰剂RQLQ评分的最小重要差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d00b294489d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796936, encodeId=dcc31e969367f, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=JEADV:替曲吉珠单抗（ tildrakizumab ）对中度至重度银屑病患者第28周停药后复发时间的研究, objectType=article, longId=216745, objectId=b9a4216e45c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9a4216e45c3, replyNumber=0, likeNumber=44, createdTime=2022-05-08, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9a4216e45c3, moduleTitle=JEADV:替曲吉珠单抗（ tildrakizumab ）对中度至重度银屑病患者第28周停药后复发时间的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9a4216e45c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796937, encodeId=f9f91e96937b8, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=BJD:瑞莎珠单抗vs司库奇尤单抗在中度至重度斑块状银屑病患者中的疗效和安全性, objectType=article, longId=216936, objectId=12a7216936f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12a7216936f0, replyNumber=0, likeNumber=46, createdTime=2022-05-30, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12a7216936f0, moduleTitle=BJD:瑞莎珠单抗vs司库奇尤单抗在中度至重度斑块状银屑病患者中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12a7216936f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796944, encodeId=e2521e969448f, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=Fezolinetant治疗中度至重度血管舒缩症状，III期研究未达到主要终点, objectType=article, longId=301019, objectId=aafd3010194a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aafd3010194a, replyNumber=0, likeNumber=38, createdTime=2022-11-07, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aafd3010194a, moduleTitle=Fezolinetant治疗中度至重度血管舒缩症状，III期研究未达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aafd3010194a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796933, encodeId=8c0d1e9693354, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=Br J Dermatol：曲妥珠单抗加局部皮质类固醇可有效且安全的治疗中度至重度特应性皮炎, objectType=article, longId=215845, objectId=09762158451c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09762158451c, replyNumber=0, likeNumber=52, createdTime=2022-01-14, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09762158451c, moduleTitle=Br J Dermatol：曲妥珠单抗加局部皮质类固醇可有效且安全的治疗中度至重度特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09762158451c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796942, encodeId=abca1e9694251, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=JACIP:Dupilumab治疗减少成人中度至重度特应性皮炎的住院治疗, objectType=article, longId=294727, objectId=65f8294e27ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65f8294e27ca, replyNumber=0, likeNumber=47, createdTime=2022-07-16, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65f8294e27ca, moduleTitle=JACIP:Dupilumab治疗减少成人中度至重度特应性皮炎的住院治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65f8294e27ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796943, encodeId=80121e9694382, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=JAK抑制剂「乌帕替尼」在华获批，用于治疗成人和12岁及以上儿童及青少年的难治性、中度至重度特应性皮炎, objectType=article, longId=299190, objectId=b29229919036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b29229919036, replyNumber=0, likeNumber=51, createdTime=2022-08-24, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b29229919036, moduleTitle=JAK抑制剂「乌帕替尼」在华获批，用于治疗成人和12岁及以上儿童及青少年的难治性、中度至重度特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b29229919036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796939, encodeId=33f41e96939e6, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=JAAD：古塞库单抗（Guselkumab）连续五年治疗中度至重度银屑病的安全性分析, objectType=article, longId=221468, objectId=b9382214685e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9382214685e, replyNumber=0, likeNumber=49, createdTime=2022-01-31, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9382214685e, moduleTitle=JAAD：古塞库单抗（Guselkumab）连续五年治疗中度至重度银屑病的安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9382214685e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796935, encodeId=487e1e96935c4, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=JAMA：IL-23 抑制剂Risankizumab 对中度至重度银屑病患者治疗结果的影响, objectType=article, longId=216683, objectId=469921668328, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=469921668328, replyNumber=0, likeNumber=55, createdTime=2022-07-30, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=469921668328, moduleTitle=JAMA：IL-23 抑制剂Risankizumab 对中度至重度银屑病患者治疗结果的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=469921668328)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796930, encodeId=cf791e9693040, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=美FDA发布强生研发的疫苗分析报告：能预防中度至重度新冠感染, objectType=article, longId=207994, objectId=ce1820e994e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce1820e994e9, replyNumber=0, likeNumber=44, createdTime=2021-03-20, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce1820e994e9, moduleTitle=美FDA发布强生研发的疫苗分析报告：能预防中度至重度新冠感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce1820e994e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796932, encodeId=09651e96932a2, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=Gastroenterology：苯扎贝特可有效改善胆汁淤积性疾病患者的中度至重度皮肤瘙痒, objectType=article, longId=215545, objectId=95512155451d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95512155451d, replyNumber=0, likeNumber=41, createdTime=2022-03-19, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95512155451d, moduleTitle=Gastroenterology：苯扎贝特可有效改善胆汁淤积性疾病患者的中度至重度皮肤瘙痒, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95512155451d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796940, encodeId=00e91e96940d4, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物, objectType=article, longId=293187, objectId=acae29318e52, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acae29318e52, replyNumber=0, likeNumber=35, createdTime=2022-09-20, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acae29318e52, moduleTitle=LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acae29318e52)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796938, encodeId=531d1e9693853, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=J Dermatolog Treat：Dermalax TM DEEP用于矫正中度至重度鼻唇沟的疗效和安全性, objectType=article, longId=218921, objectId=017b21892120, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=017b21892120, replyNumber=0, likeNumber=33, createdTime=2022-09-15, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=017b21892120, moduleTitle=J Dermatolog Treat：Dermalax TM DEEP用于矫正中度至重度鼻唇沟的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=017b21892120)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796931, encodeId=eab91e969318e, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=JAMA子刊：短期内的严重损伤不代表中度至重度颅脑创伤预后不良, objectType=article, longId=214751, objectId=efdd214e515c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efdd214e515c, replyNumber=0, likeNumber=52, createdTime=2022-05-15, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efdd214e515c, moduleTitle=JAMA子刊：短期内的严重损伤不代表中度至重度颅脑创伤预后不良, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efdd214e515c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796934, encodeId=11661e96934b2, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=JCEM：利妥昔单抗靶向治疗在活动性中度至重度Graves眼病患者的疗效, objectType=article, longId=216674, objectId=c00c2166e4fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c00c2166e4fb, replyNumber=0, likeNumber=30, createdTime=2022-02-13, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c00c2166e4fb, moduleTitle=JCEM：利妥昔单抗靶向治疗在活动性中度至重度Graves眼病患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c00c2166e4fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796929, encodeId=a8a21e9692934, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=Dig Dis Sci: 中度至重度溃疡性结肠炎患者尝试使用英夫利昔单抗时代表5-氨基水杨酸酯治疗就无效了, objectType=article, longId=203612, objectId=5cb720361244, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cb720361244, replyNumber=0, likeNumber=39, createdTime=2021-05-30, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cb720361244, moduleTitle=Dig Dis Sci: 中度至重度溃疡性结肠炎患者尝试使用英夫利昔单抗时代表5-氨基水杨酸酯治疗就无效了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cb720361244)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796927, encodeId=859f1e96927ef, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=J Allergy Clin Immunol Pract：糠酸氟替卡松鼻喷雾剂在中度至重度、持续性、常年性过敏性鼻炎患者中的按需使用与常规使用的比较, objectType=article, longId=202269, objectId=975d202269ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=975d202269ea, replyNumber=0, likeNumber=39, createdTime=2021-02-11, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=975d202269ea, moduleTitle=J Allergy Clin Immunol Pract：糠酸氟替卡松鼻喷雾剂在中度至重度、持续性、常年性过敏性鼻炎患者中的按需使用与常规使用的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=975d202269ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796925, encodeId=9c401e96925b4, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, objectTitle=J Clin Periodontol：中度至重度牙周炎患者的牙周支持疗法, objectType=article, longId=196050, objectId=f5ac19605067, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5ac19605067, replyNumber=0, likeNumber=47, createdTime=2021-03-22, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5ac19605067, moduleTitle=J Clin Periodontol：中度至重度牙周炎患者的牙周支持疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5ac19605067)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

中度至重度

2020-05-29

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

JAMA Dermatol：特定配方的维A酸前体可有效治疗中度至重度面部光损伤

2023-01-30

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

J Am Acad Dermatol：阿布昔替尼可有效治疗中度至重度特应性皮炎，无论之前患者对度匹鲁单抗的反应如何

2023-07-06

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

Allergy：中度至重度过敏成人中，草树过敏免疫疗法与安慰剂RQLQ评分的最小重要差异

2022-10-12

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

JEADV:替曲吉珠单抗（ tildrakizumab ）对中度至重度银屑病患者第28周停药后复发时间的研究

2022-05-08

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

BJD:瑞莎珠单抗vs司库奇尤单抗在中度至重度斑块状银屑病患者中的疗效和安全性

2022-05-30

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

Fezolinetant治疗中度至重度血管舒缩症状，III期研究未达到主要终点

2022-11-07

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

Br J Dermatol：曲妥珠单抗加局部皮质类固醇可有效且安全的治疗中度至重度特应性皮炎

2022-01-14

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

JACIP:Dupilumab治疗减少成人中度至重度特应性皮炎的住院治疗

2022-07-16

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

JAK抑制剂「乌帕替尼」在华获批，用于治疗成人和12岁及以上儿童及青少年的难治性、中度至重度特应性皮炎

2022-08-24

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

JAAD：古塞库单抗（Guselkumab）连续五年治疗中度至重度银屑病的安全性分析

2022-01-31

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

JAMA：IL-23 抑制剂Risankizumab 对中度至重度银屑病患者治疗结果的影响

2022-07-30

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

美FDA发布强生研发的疫苗分析报告：能预防中度至重度新冠感染

2021-03-20

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

Gastroenterology：苯扎贝特可有效改善胆汁淤积性疾病患者的中度至重度皮肤瘙痒

2022-03-19

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物

2022-09-20

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

J Dermatolog Treat：Dermalax TM DEEP用于矫正中度至重度鼻唇沟的疗效和安全性

2022-09-15

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

JAMA子刊：短期内的严重损伤不代表中度至重度颅脑创伤预后不良

2022-05-15

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

JCEM：利妥昔单抗靶向治疗在活动性中度至重度Graves眼病患者的疗效

2022-02-13

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

Dig Dis Sci: 中度至重度溃疡性结肠炎患者尝试使用英夫利昔单抗时代表5-氨基水杨酸酯治疗就无效了

2021-05-30

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

J Allergy Clin Immunol Pract：糠酸氟替卡松鼻喷雾剂在中度至重度、持续性、常年性过敏性鼻炎患者中的按需使用与常规使用的比较

2021-02-11

liuyong2980 (审核中...)

前往app查看评论内容

#中度至重度#

J Clin Periodontol：中度至重度牙周炎患者的牙周支持疗法

2021-03-22

科室
- - 订阅+
  - 更多科室
工具
服务